Tango for Neuropathy

(DAANCE Trial)

Overseen By Lise Worthen-Chaudhari, PhD, MFA, CMES

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Ohio State University Comprehensive Cancer Center

Disqualifiers: Vestibular dysfunction, Poorly controlled diabetes, Non-ambulatory, Hearing impairment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 12

140 Participants Needed

Trial Summary

What is the purpose of this trial?

Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.

Research Team

Lise B Worthen-Chaudhari, PhD, MFA, CMES

Principal Investigator

Ohio State University

Maryam B Lustberg, MD, MPH

Principal Investigator

Yale University

Eligibility Criteria

This trial is for breast cancer survivors who finished taxane-based chemotherapy at least 3 months ago, are experiencing neuropathy symptoms, and have a risk of falling. They must be able to follow study instructions. People with vestibular dysfunction, severe diabetes, hearing loss, or unstable medical conditions that prevent physical activity cannot join.

Inclusion Criteria

My breast cancer is at any stage from I to IV, including if it has spread.

I am experiencing symptoms of nerve pain or damage from chemotherapy.

Able to understand and comply with directions associated with testing and study treatments

Exclusion Criteria

Pre-existing vestibular dysfunction

My doctor says I can't join in the exercise study due to another health issue.

I have severe hearing loss in both ears.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Control

Participants receive 4 weeks of usual care followed by optional 1-way crossover to 8 weeks of partnered, adapted tango dance

4 weeks

1 visit (in-person)

Experimental

Participants receive 8 weeks of partnered, adapted tango dance

8 weeks

8 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

3 visits (in-person)

Treatment Details

Interventions

• Adapted Argentine Tango

Trial Overview The DAANCE trial is testing Adapted Argentine Tango as a treatment for chemotherapy-induced neuropathy in breast cancer survivors. It aims to improve motor control and reduce symptoms while encouraging participation in the therapy.

Participant Groups

Group I: Experimental Experimental Treatment 1 Intervention

8 weeks of intervention (partnered, adapted tango dance)

Group II: Control Active Control 1 Intervention

4 weeks of usual care followed by optional 1-way crossover to 8 weeks of Intervention (partnered, adapted tango dance)

Who Is Running the Clinical Trial?

Ohio State University Comprehensive Cancer Center

Lead Sponsor

Trials

350

Recruited

295,000+

Emory University

Collaborator

Trials

1,735

Recruited

2,605,000+

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+

Yale University

Collaborator

Trials

1,963

Recruited

3,046,000+